Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
Alessandra Carobbio(Ospedale Papa Giovanni XXIII), Tiziano Barbui(University of Bergamo), Irene Bertozzi(University of Padua), Ayalew Tefferi(Mayo Clinic), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Maria Luigia Randi(University of Padua), Heinz Gisslinger(Medical University of Vienna), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Elisa Rumi(University of Pavia), Elisabetta Antonioli(Azienda Ospedaliero-Universitaria Careggi), Marco Ruggeri(Ospedale San Bortolo), Guido Finazzi(Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini"), Jüergen Thiele(University of Cologne), Naseema Gangat(Mayo Clinic in Arizona), Francesco Rodeghiero(Ospedale San Bortolo), Francesco Passamonti(University of Milan)
Cited by 448
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k